Explain the mechanism and regulation of HCl secretion. Describe the protective role of “gastric mucosal barrier.” Add a note on the physiological basis of treatment of gastric ulcer.

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Loading Image

Searching PubMed

peptic ulcer disease treatment guidelines proton pump inhibitor

I now have all the material I need to write a thorough, well-sourced answer. Let me compose the full response.

HCl Secretion: Mechanism, Regulation, Gastric Mucosal Barrier, and Treatment of Peptic Ulcer

1. Mechanism of HCl Secretion

Site and Cell of Origin

HCl is secreted exclusively by parietal cells (oxyntic cells) located in the oxyntic glands of the fundus and body of the stomach (the proximal ~80%). These glands also contain chief cells (pepsinogen), mucous neck cells, and ECL cells (histamine). The secreted acid solution contains approximately 160 mmol/L HCl, with a pH of ~0.8 - meaning the H+ concentration is about 3 million times that of arterial blood. Generating this gradient requires over 1500 calories of energy per litre of gastric juice.

Intracellular Canaliculi

Each parietal cell contains large branching intracellular canaliculi lined with villus-like projections where the actual acid is formed. From these canaliculi, HCl is conducted to the secretory end of the cell and discharged into the gland lumen.

Ionic Steps of HCl Formation

The following figure from Guyton illustrates the full mechanism:

Postulated mechanism for secretion of hydrochloric acid by the parietal cell

Figure 65.6 - Guyton & Hall Textbook of Medical Physiology

Step-by-step:

Water dissociation: Inside the parietal cell, H2O dissociates into H+ and OH-.
H+-K+ ATPase (proton pump): The H+ is actively pumped into the canalicular lumen in exchange for K+ via the H+-K+ ATPase located on the apical (canalicular) membrane. This is the primary driving force of acid secretion and is the direct target of proton pump inhibitors (PPIs).
CO2 hydration: The OH- that accumulates inside the cell combines with CO2 (from cellular metabolism or from blood) to form HCO3-, a reaction catalyzed by carbonic anhydrase.
HCO3-/Cl- exchanger: HCO3- is transported across the basolateral membrane into the extracellular fluid (and then blood) in exchange for Cl-, which enters the cell. This is the "alkaline tide" - gastric venous blood has a higher pH than arterial blood during active secretion.
Cl- secretion: Cl- exits the cell through chloride channels into the canaliculus, meeting the secreted H+ to form HCl.
K+ recycling: K+ that entered via the H+-K+ ATPase is recycled back into the canalicular lumen through K+ channels, keeping the pump running.
Water: Follows by osmosis, producing a final secretion of H2O + HCl (~150-160 mEq/L) + KCl (~15 mEq/L) + small amounts of NaCl.

On the basolateral side, a Na+-K+ ATPase maintains the intracellular ionic environment by pumping Na+ out and K+ in.

2. Regulation of HCl Secretion

Three Primary Stimulants

HCl secretion is controlled by three main secretagogues acting on parietal cells, each binding specific receptors:

Stimulant	Receptor on Parietal Cell	Source	Second Messenger
Acetylcholine (ACh)	Muscarinic M3	Vagus nerve / enteric plexus	IP3/DAG (Ca2+)
Gastrin	CCK-B (gastrin) receptor	G cells of antrum	Ca2+
Histamine	H2 receptor	ECL cells (paracrine)	cAMP

All three pathways ultimately activate the H+-K+ ATPase, but they act synergistically - blocking one pathway reduces the response to the others.

The ECL Cell as the Central Relay

Parietal cells work in close association with enterochromaffin-like (ECL) cells in the oxyntic glands. Gastrin (from G cells) and ACh both stimulate ECL cells to release histamine, which then acts in a paracrine fashion directly on adjacent parietal cell H2 receptors. ECL-derived histamine is the most potent stimulant of acid secretion in humans.

Somatostatin: The Key Inhibitor

Somatostatin from antral D cells is the primary physiological brake on acid secretion. It inhibits acid secretion at three levels:

Directly on parietal cells (D cell - parietal cell paracrine contact)
On ECL cells (reduces histamine release)
On G cells (reduces gastrin release)

Low antral pH stimulates somatostatin release - a negative feedback loop.

Phases of Gastric Secretion

Figure 65.7 - Guyton & Hall Textbook of Medical Physiology

Cephalic Phase (~30% of meal response)

Triggered by sight, smell, taste, or even thought of food
Mediated via the cerebral cortex → hypothalamus/amygdala → dorsal motor nucleus of vagus → gastric vagal efferents
ACh released directly stimulates parietal cells, chief cells, mucous cells, and G cells

Gastric Phase (~60% of meal response)

Triggered by distension and protein content in the stomach
Three mechanisms operate: (1) long vagovagal reflexes, (2) local enteric reflexes, (3) gastrin release from antral G cells
This is the dominant phase and accounts for most of the ~1500 mL daily acid output

Intestinal Phase (~10%)

Small amount of gastrin released by duodenal mucosa when chyme enters the duodenum
Soon followed by inhibitory signals as the small intestine fills

Inhibitory Mechanisms (Intestinal Feedback)

Once chyme enters the small intestine, several mechanisms inhibit further secretion:

Enterogastric reflex: Distension, acid, fat, or hyperosmolarity in the duodenum triggers a reverse reflex (via myenteric plexus and sympathetics) that inhibits gastric secretion
Secretin: Released by S cells in response to duodenal acid; inhibits gastrin secretion and stimulates bicarbonate secretion
GIP (glucose-dependent insulinotropic peptide), VIP, and somatostatin all have moderate inhibitory effects

3. The Gastric Mucosal Barrier

The stomach must protect itself from its own secretions - 160 mEq/L HCl and active pepsin. This protection is provided by a multi-layered gastric mucosal barrier.

Components (from Schwartz's Principles of Surgery)

Layer	Mechanism
Mucus-bicarbonate layer	Viscid gel of mucopolysaccharides secreted by surface epithelial cells (SECs) and pyloric glands; contains HCO3- creating a favorable pH gradient (pH 7 near mucosa vs pH 2 in lumen)
Epithelial barrier	Intact cell membranes and tight junctions between epithelial cells prevent H+ from entering the interstitium
Hydrophobic phospholipids	Surfactant-like phospholipids on the mucosal surface repel aqueous acid
Restitution	Sloughed or denuded SECs are rapidly replaced by migration of adjacent cells
Mucosal blood flow (reactive hyperemia)	Rich submucosal blood supply removes any back-diffused H+; buffers acid with the alkaline tide from parietal cell HCO3- secretion
Afferent sensory neurons	Protective reflexes triggered by mucosal irritation; blocked by topical anesthetics

Key Mediators of Cytoprotection

Prostaglandins (PGE2, PGI2): Stimulate mucus and bicarbonate secretion, maintain mucosal blood flow, inhibit acid secretion. NSAIDs block prostaglandin synthesis via COX inhibition, which is why they are a major cause of mucosal injury.
Nitric oxide (NO): Vasodilatory; maintains mucosal blood flow
Epidermal growth factor (EGF): Promotes epithelial repair and restitution
Calcitonin gene-related peptide (CGRP) and gastrin-releasing peptide (GRP): Protective neuropeptides

Barrier Breakers

The mucosal barrier is damaged by:

NSAIDs / aspirin: Inhibit prostaglandin synthesis; allow back-diffusion of H+
Alcohol: Direct mucosal damage and increased permeability
Bile reflux: Disrupts the lipid layer
H. pylori: Produces urease (generates NH3, which is locally toxic) and disrupts tight junctions and mucus production
Ischaemia: The stomach is the most sensitive part of the GI tract to ischaemia and the slowest to recover after hypovolaemic shock - this explains the high incidence of stress ulceration

When barrier function fails, H+ back-diffuses into the lamina propria and submucosa. This triggers a protective increase in mucosal blood flow; if this response is also blocked (e.g., by shock or NSAIDs), gross mucosal ulceration results.

4. Physiological Basis of Treatment of Gastric Ulcer

Gastric ulceration reflects an imbalance between aggressive factors (HCl, pepsin, H. pylori, NSAIDs, bile) and defensive factors (mucus, bicarbonate, blood flow, prostaglandins). Treatment targets this imbalance.

A. Reducing Acid Secretion

1. Proton Pump Inhibitors (PPIs) - e.g., omeprazole, esomeprazole, pantoprazole

Target the final common pathway - the H+-K+ ATPase on the parietal cell apical membrane
PPIs are prodrugs that become activated in the acidic canalicular environment, forming a covalent bond with cysteine residues on the pump - providing long-lasting inhibition (irreversible until new pump protein is synthesized)
Most effective acid suppression available; the cornerstone of ulcer treatment
Omeprazole 20 mg twice daily is equivalent to standard PPI dosing for complicated ulcer disease

2. H2-Receptor Antagonists (H2RAs) - e.g., ranitidine, famotidine

Block histamine's action at H2 receptors on parietal cells, reducing cAMP-mediated acid secretion
Less powerful than PPIs (histamine is not the only stimulant) but useful for maintenance or milder disease

3. Anticholinergic agents / Vagotomy

Block muscarinic M3 receptors or cut the vagal drive to parietal cells and G cells
Surgical vagotomy (truncal or highly selective) reduces both cephalic and gastric phase acid output
Highly selective vagotomy spares the hepatic and celiac branches, preserving gastric emptying

4. Antacids (e.g., aluminium hydroxide, magnesium hydroxide)

Directly neutralize secreted HCl in the lumen: HCl + NaHCO3 → NaCl + H2O + CO2
Raise intragastric pH, inactivating pepsin (inactive above pH 5)
Provide rapid symptomatic relief but no mucosal healing; used adjunctively

B. Eradicating H. pylori

H. pylori infects the gastric mucosa, induces chronic inflammation, disrupts the mucosal barrier, and increases gastrin secretion
Triple therapy: PPI + clarithromycin + amoxicillin (or metronidazole) for 10-14 days eradicates the organism
Eradication dramatically reduces ulcer relapse rates (from ~70-80% to <10% at 1 year)

C. Enhancing Mucosal Defense

1. Sucralfate

A sucrose-sulfate-aluminium complex that binds to ulcer craters, forming a protective coating
Stimulates prostaglandin synthesis and EGF release; buffers acid locally
Acts independently of acid suppression - a pure "mucosal defense enhancer"

2. Bismuth salts

Coat ulcer base; also have direct anti-H. pylori activity
Part of quadruple therapy regimens

3. Prostaglandin analogues (e.g., misoprostol)

Exogenous PGE1 analogue: stimulates mucus and bicarbonate secretion, reduces acid secretion, maintains mucosal blood flow
Used particularly to prevent NSAID-induced ulcers (where endogenous prostaglandins are depleted)

D. Avoiding Ulcerogenic Factors

Withdraw NSAIDs if possible; use COX-2-selective inhibitors (lower GI risk) with PPI cover if NSAIDs are essential
Cease alcohol and smoking (smoking reduces bicarbonate secretion and delays ulcer healing)

Summary Table

Mechanism	Drug/Intervention
Irreversible H+-K+ ATPase block	PPIs (omeprazole, pantoprazole)
H2 receptor block	Ranitidine, famotidine
Acid neutralization	Antacids (MgOH, AlOH)
Muscarinic block / vagotomy	Pirenzepine; surgical vagotomy
H. pylori eradication	Triple/quadruple therapy
Mucosal coating / cytoprotection	Sucralfate, bismuth
Prostaglandin replacement	Misoprostol
Reduce NSAID-induced injury	COX-2 inhibitors + PPI

Sources:

Guyton and Hall Textbook of Medical Physiology (14th ed.), pp. 802-804
Schwartz's Principles of Surgery (11th ed.) - Gastric Mucosal Barrier (Table 26-3)
Bailey and Love's Short Practice of Surgery (28th ed.) - Gastric mucus and the gastric mucosal barrier
Sabiston Textbook of Surgery - Stimulated Acid Secretion; Other Gastric Secretory Products
Goldman-Cecil Medicine - Medical Therapy for Peptic Ulcer Disease

This is a shared conversation. Sign in to Orris to start your own chat.